ArticlePloS one2024
Contrast vector imaging for differential diagnosis of focal liver lesions: Analysis of tumoral vascular structures and flow characteristics.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microvascular Imaging of Hepatic Hemangiomas.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the efficacy of contrast vector imaging (CVI) in detecting tumoral vascular structures and flow characteristics of focal liver lesions (FLLs) for differential diagnosis. MATERIALS AND
methodsIn this prospective study, 65 participants with FLLs underwent CEUS using SonoVue with high-frame-rate imaging technique between July 2019 and October 2020. CVI was obtained by post-processing arterial cine imaging of CEUS. Tumoral vascular structures, velocity histogram, and mean velocities were compared among hepatocellular carcinoma (HCC), non-HCC malignancies, and benign tumors using the Chi-square and Kruskal-Wallis tests, respectively. The areas under the receiver operating characteristic curve (AUC) of CEUS in determining HCC probability was compared to that of CEUS with CVI using a z-test.
resultsCVI was technically successful in 52 of 65 (80%) participants (19 HCCs, 13 non-HCC malignancies, and 20 benign tumors). The detectability of tumoral vascular structures was significantly higher in CEUS with CVI, compared to CEUS alone (46.2% [24/52] vs. 100.0% [52/52], p<0.001). On CEUS with CVI, complex intratumoral and peripheral vessels were frequent in HCCs (100% of HCCs, 46.2% of non-HCC malignancies, and 70.0% of benign tumors), while detour vessels were frequent in non-HCC malignancies (none of HCCs, 53.8% of non-HCC malignancies, and 10.0% of benign tumors) (p<0.001). The mean velocity of HCC (26.3 mm/s) was the highest, while that of non-HCC malignancy (20.6 mm/s) was the lowest (p<0.001). CEUS with CVI showed higher AUC, compared to CEUS in both reviewers (0.851 vs. 0.963, p = 0.005 for reviewer 1; 0.853 vs. 0.982, p = 0.023 for reviewer 2).
conclusionCEUS with CVI better visualized vascular structures and flow characteristics of FLLs, and showed better diagnostic performance in determining HCC probability than CEUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.